Natco Pharma Ltd
NATCOPHARMNatco Pharma Ltd
NATCOPHARM![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/moderate_risk.png)
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
16.41 | 5.51 | 0.65% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast from 9 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Natco Pharma Limited is a research and development (R&D)-focused pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,054.10 | 2,034.10 | 2,225.20 | 2,224.70 | 2,022.40 | 2,155.70 | 2,043.80 | 2,811.70 | 4,126.90 | 4,377.40 | ||||||||||
Raw Materials | 318.90 | 617.90 | 436.40 | 388.10 | 456.80 | 559.50 | 577.70 | 651.00 | 2,247.40 | 2,192.70 | ||||||||||
Power & Fuel Cost | 43.70 | 50.50 | 56.20 | 59.60 | 62.40 | 61.10 | 76.40 | 81.90 | ||||||||||||
Employee Cost | 179.80 | 243.20 | 325.60 | 355.90 | 375.00 | 414.90 | 444.80 | 486.70 | ||||||||||||
Selling & Administrative Expenses | 180.90 | 299.60 | 304.50 | 351.10 | 311.60 | 300.90 | 367.70 | 388.80 | ||||||||||||
Operating & Other expenses | 53.40 | 125.60 | 133.70 | 145.00 | 126.60 | 109.50 | 214.70 | 163.10 | ||||||||||||
EBITDA | 277.40 | 697.30 | 968.80 | 925.00 | 690.00 | 709.80 | 362.50 | 1,040.20 | 1,879.50 | 2,184.70 | ||||||||||
Depreciation/Amortization | 50.80 | 54.40 | 66.20 | 81.00 | 99.80 | 116.90 | 142.60 | 163.80 | 186.80 | 187.40 | ||||||||||
PBIT | 226.60 | 642.90 | 902.60 | 844.00 | 590.20 | 592.90 | 219.90 | 876.40 | 1,692.70 | 1,997.30 | ||||||||||
Interest & Other Items | 22.90 | 18.50 | 15.40 | 19.30 | 21.50 | 13.30 | 17.70 | 14.50 | 19.20 | 20.20 | ||||||||||
PBT | 203.70 | 624.40 | 887.20 | 824.70 | 568.70 | 579.60 | 202.20 | 861.90 | 1,673.50 | 1,977.10 | ||||||||||
Taxes & Other Items | 46.60 | 138.40 | 191.00 | 180.30 | 107.90 | 138.70 | 32.20 | 146.60 | 285.20 | 340.60 | ||||||||||
Net Income | 157.10 | 486.00 | 696.20 | 644.40 | 460.80 | 440.90 | 170.00 | 715.30 | 1,388.30 | 1,636.50 | ||||||||||
EPS | 9.23 | 27.89 | 38.81 | 35.09 | 25.26 | 24.20 | 9.32 | 39.22 | 77.34 | 89.69 | ||||||||||
DPS | 1.25 | 6.75 | 8.25 | 6.25 | 6.75 | 5.25 | 4.50 | 5.50 | 9.50 | 9.50 | ||||||||||
Payout ratio | 0.14 | 0.24 | 0.21 | 0.18 | 0.27 | 0.22 | 0.48 | 0.14 | 0.12 | 0.11 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Natco Pharma Ltd | 19.34 | 5.51 | 0.65% |
Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
Cipla Ltd | 31.71 | 4.88 | 0.80% |
Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare NATCOPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.02%
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 1.31%
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 1.41%
Top 5 Mutual Funds holding Natco Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
TATA MUTUAL FUND EQ P/E DIRECT GROWTH OPEN ENDED Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7392% | Percentage of the fund’s portfolio invested in the stock 2.24% | Change in the portfolio weight of the stock over the last 3 months 1.25% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 18/55 (+15) |
Tata Small Cap Fund-Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4563% | Percentage of the fund’s portfolio invested in the stock 1.45% | Change in the portfolio weight of the stock over the last 3 months 0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 29/54 (+8) |
SBI FUNDS MANAGEMENT PVT LTD#SBI MF-SBI MAGNUM MIDCAP FUND DIRECT PL GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3659% | Percentage of the fund’s portfolio invested in the stock 0.48% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 33/86 (+1) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Natco Pharma Ltd
Events
Dividend Trend
Dividend Yield
Current dividend yield is 0.65%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹6.46 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 23, 2024
Dividend/Share
₹3.00
Ex DateEx Date
Aug 23, 2024
Cash Dividend
Ex DateEx DateFeb 26, 2024
Dividend/Share
₹1.25
Ex DateEx Date
Feb 26, 2024
Cash Dividend
Ex DateEx DateNov 24, 2023
Dividend/Share
₹1.25
Ex DateEx Date
Nov 24, 2023
Cash Dividend
Ex DateEx DateAug 22, 2023
Dividend/Share
₹7.00
Ex DateEx Date
Aug 22, 2023
Cash Dividend
Ex DateEx DateFeb 21, 2023
Dividend/Share
₹1.25
Ex DateEx Date
Feb 21, 2023
Natco Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1570.8, up 1.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.09% on the day, quoting at 24833.9. The Sensex is at 81102.86, up 0.06%. Natco Pharma Ltd has added around 19.18% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has added around 7.56% in last one month and is currently quoting at 22546.1, down 0.25% on the day. The volume in the stock stood at 10.92 lakh shares today, compared to the daily average of 12.32 lakh shares in last one month.The PE of the stock is 18.07 based on TTM earnings ending June 24.Powered by Capital Market - Live
Natco Pharma has fixed 23 August 2024 as record date for second interim dividend for FY 2024-25. The dividend will be paid from 30 August 2024. Powered by Capital Market - Live
Natco Pharma announced that the 41th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
Natco Pharma announced that the Board of Directors of the Company at its meeting held on 12 August 2024, inter alia, have recommended the dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.Powered by Capital Market - Live
Revenue from operations was at Rs 1,362.6 crore in Q1 FY25, up 19.47% from Rs 1140.5 crore posted in Q1 FY24. The company said that the growth in revenue and profits were driven primarily by exports formulation business. Total income jumped 21.59% year on year to Rs 1,410.7 crore in the quarter ended 30 June 2024. Profit before tax in Q1 FY25 stood at Rs 803.6 crore, up 60.72% as against Rs 500 crore reported in the same period a year ago. The company's revenue from API stood at Rs 39.2 crore (down 47.8% YoY), income from domestic formulations was at Rs 102.2 crore (down 22.81% YoY) and revenue from crop health sciences (CHS) came in at Rs 15.6 crore (down 65.1% YoY) during the period under review. On the other hand, revenue from exports formulations jumped 36.86% YoY to Rs 1,210.10 crore during the quarter. Meanwhile, the company's board declared an interim dividend of Rs 3 per equity share in FY25, subject to approval of shareholders. The record date for the same is fixed on Friday, 23 August 2024. The payment of the dividend will start from 30 August 2024. Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like United States of America and Europe.Powered by Capital Market - Live
Net profit of Natco Pharma rose 59.05% to Rs 668.50 crore in the quarter ended June 2024 as against Rs 420.30 crore during the previous quarter ended June 2023. Sales rose 19.47% to Rs 1362.60 crore in the quarter ended June 2024 as against Rs 1140.50 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1362.601140.50 19 OPM %59.0646.30 - PBDT847.70543.50 56 PBT803.60500.00 61 NP668.50420.30 59 Powered by Capital Market - Live
Natco Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1439.4, up 1.76% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 24269.55. The Sensex is at 79387.27, down 0.1%. Natco Pharma Ltd has added around 19.96% in last one month. Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has added around 7.67% in last one month and is currently quoting at 22036.95, up 0.88% on the day. The volume in the stock stood at 8.79 lakh shares today, compared to the daily average of 10.28 lakh shares in last one month.The PE of the stock is 19.39 based on TTM earnings ending March 24.Powered by Capital Market - Live
Natco Pharma announced the sad demise of Dr. M.U.R. Naidu, Independent Director of the Company on 30 July 2024.Powered by Capital Market - Live
Natco Pharma announced that Sanivarapu Ravi Prakash Reddy, Senior Vice President - Operations, Pharma Division, Kothur, Rangareddy District, Telangana has resigned and relieved w.e.f. 25 July 2024. Powered by Capital Market - Live
Natco Pharma will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 13.15%, vs industry avg of 9.21%
Increasing Market Share
Over the last 5 years, market share increased from 0.98% to 1.09%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 16.59%, vs industry avg of 15.17%